Sign in now to see personalised content appear here.
You can also see your reading history and subscription details on your subscriber page.
Using Wacker E.coli-based ESETEC secretion technology
For process development and early stage clinical supply of monoclonal antibodies
For the production of PASylated therapeutic proteins
Cobra to provide cell line development, cell banking, process development, scale-up, GMP production and stability studies
Human antibody will be evaluated for the treatment of selected cancers
Adds single-use manufacturing technology to portfolio
Ylanthia will show higher success rates and shorter timelines in antibody drug development